Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarter
Combined commercial launch of vonoprazan for erosive esophagitis and H. pylori indications expected Q4 2023, if approved
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.